madman
Super Moderator
* To date there's only been one randomized study testing BAT
14:05 Stop & Watch: The TRANSFORMER trial—did BAT actually work?
For decades, men with prostate cancer have been told that testosterone is like gasoline on a fire. But what if, under the right conditions, testosterone could actually become part of the treatment?
In this episode of the Dr. Geo Prostate Podcast, Dr. Geo sits down with Dr. Michael Schweizer, board-certified medical oncologist at Fred Hutchinson Cancer Center and one of the pioneers of Bipolar Androgen Therapy (BAT), to explore one of the most controversial and exciting developments in advanced prostate cancer.
Together, they unpack the science behind BAT, why high-dose testosterone may actually damage treatment-resistant prostate cancer cells, and how this approach could restore sensitivity to therapies that previously stopped working.
This isn't speculation—it's a deep dive into the biology, the clinical trials, the limitations, and where the research is headed next.
In this episode, you'll learn:
* Why the old "testosterone feeds prostate cancer" belief is being challenged
* What Bipolar Androgen Therapy (BAT) actually is
* Why BAT is currently studied only in castration-resistant prostate cancer
* How supraphysiologic testosterone may overwhelm resistant cancer cells
* Why BAT may make drugs like enzalutamide work again
* The surprising quality-of-life benefits seen in clinical trials
* Which patients may benefit most from BAT
* Why genetic testing is becoming increasingly important
* Current BAT clinical trials and what the future may hold
Whether you're a patient, caregiver, physician, or simply interested in the latest advances in prostate cancer treatment, this conversation offers an evidence-based look at a therapy that could reshape how resistant prostate cancer is managed.
Chapters
00:00 Introduction: Can Testosterone Treat Prostate Cancer?
02:00 The surprising origin of Bipolar Androgen Therapy (BAT)
04:10 Stop & Watch: Why Charles Huggins hinted at this decades ago
07:10 Why ordinary testosterone therapy failed—and BAT didn't
08:20 Stop & Watch: The BAT protocol explained (400 mg every 28 days)
10:00 Why BAT is only used in castration-resistant prostate cancer
14:05 Stop & Watch: The TRANSFORMER trial—did BAT actually work?
16:20 Stop & Watch: How BAT may make failed treatments work again
20:30 Stop & Watch: If testosterone isn't the enemy...why do we suppress it?
22:10 Must Watch: The biology that completely changes how we think about testosterone
24:10 How BAT damages cancer DNA
26:30 BAT, quality of life, and survival—what the evidence really shows
30:00 Stop & Watch: The sequencing strategy that could add months of cancer control
31:30 Which patients may respond best to BAT?
33:20 Must Watch: Why every advanced prostate cancer patient should consider genetic testing
36:00 Can someone on ADT simply start testosterone?
40:00 Where BAT fits among today's prostate cancer treatments
43:00 Stop & Watch: BAT + Lutetium PSMA—the next frontier
45:00 How to find BAT clinical trials
47:00 Should hormone therapy ever be stopped?
53:00 Final thoughts
14:05 Stop & Watch: The TRANSFORMER trial—did BAT actually work?
For decades, men with prostate cancer have been told that testosterone is like gasoline on a fire. But what if, under the right conditions, testosterone could actually become part of the treatment?
In this episode of the Dr. Geo Prostate Podcast, Dr. Geo sits down with Dr. Michael Schweizer, board-certified medical oncologist at Fred Hutchinson Cancer Center and one of the pioneers of Bipolar Androgen Therapy (BAT), to explore one of the most controversial and exciting developments in advanced prostate cancer.
Together, they unpack the science behind BAT, why high-dose testosterone may actually damage treatment-resistant prostate cancer cells, and how this approach could restore sensitivity to therapies that previously stopped working.
This isn't speculation—it's a deep dive into the biology, the clinical trials, the limitations, and where the research is headed next.
In this episode, you'll learn:
* Why the old "testosterone feeds prostate cancer" belief is being challenged
* What Bipolar Androgen Therapy (BAT) actually is
* Why BAT is currently studied only in castration-resistant prostate cancer
* How supraphysiologic testosterone may overwhelm resistant cancer cells
* Why BAT may make drugs like enzalutamide work again
* The surprising quality-of-life benefits seen in clinical trials
* Which patients may benefit most from BAT
* Why genetic testing is becoming increasingly important
* Current BAT clinical trials and what the future may hold
Whether you're a patient, caregiver, physician, or simply interested in the latest advances in prostate cancer treatment, this conversation offers an evidence-based look at a therapy that could reshape how resistant prostate cancer is managed.
Chapters
00:00 Introduction: Can Testosterone Treat Prostate Cancer?
02:00 The surprising origin of Bipolar Androgen Therapy (BAT)
04:10 Stop & Watch: Why Charles Huggins hinted at this decades ago
07:10 Why ordinary testosterone therapy failed—and BAT didn't
08:20 Stop & Watch: The BAT protocol explained (400 mg every 28 days)
10:00 Why BAT is only used in castration-resistant prostate cancer
14:05 Stop & Watch: The TRANSFORMER trial—did BAT actually work?
16:20 Stop & Watch: How BAT may make failed treatments work again
20:30 Stop & Watch: If testosterone isn't the enemy...why do we suppress it?
22:10 Must Watch: The biology that completely changes how we think about testosterone
24:10 How BAT damages cancer DNA
26:30 BAT, quality of life, and survival—what the evidence really shows
30:00 Stop & Watch: The sequencing strategy that could add months of cancer control
31:30 Which patients may respond best to BAT?
33:20 Must Watch: Why every advanced prostate cancer patient should consider genetic testing
36:00 Can someone on ADT simply start testosterone?
40:00 Where BAT fits among today's prostate cancer treatments
43:00 Stop & Watch: BAT + Lutetium PSMA—the next frontier
45:00 How to find BAT clinical trials
47:00 Should hormone therapy ever be stopped?
53:00 Final thoughts
